We spend a lot of time thinking about the difficult people in our lives—the friend who can't take feedback, the partner who always has to be right, the coworker who turns everything into a fight. But ...

One idle evening last October, Mehtaab Sawhney took up an old pastime. He began perusing the website erdosproblems.com, an updated record of the 1,179 conjectures left behind by the eccentric and ...

What are the most pressing global crises in 2026? Each year, the International Rescue Committee’s (IRC) Emergency Watchlist identifies the countries at greatest risk of new or worsening humanitarian ...

Recursive language models (RLMs) are an inference technique developed by researchers at MIT CSAIL that treat long prompts as an external environment to the model. Instead of forcing the entire prompt ...

Recursion Pharmaceuticals utilizes a proprietary operating system (OS) and an AI-powered algorithm that continuously runs virtual experiments, testing compounds against a library of human genes to ...

In October 2024, news broke that Facebook parent company Meta had cracked an "impossible" problem that had stymied mathematicians for a century. In this case, the solvers weren't human. An artificial ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...